At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses ongoing clinical studies by the German CLL Study Group (GCLLSG) that are investigating new therapies for patients with chronic lymphocytic leukaemia (CLL), including obinutuzumab in combination with chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens.
Ongoing studies by the German CLL study group (GCLLSG)
3rd July 2015
Hematology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?